Back to Gene
MLC1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

MLC1 gene

The MLC1 gene provides instructions for a protein found primarily in the brain that is essential for maintaining the health and function of astroglial cells.

Normal Function

The MLC1 gene provides instructions for making a protein found primarily in the brain, though it is also present in the spleen and white blood cells (leukocytes). Within the brain, the MLC1 protein is located in astroglial cells, a specialized type of glial cell that protects and maintains neurons.

The MLC1 protein functions at the junctions connecting neighboring astroglial cells. While its exact role is not fully understood, research suggests it may control the flow of fluids into cells or regulate the strength of cell-to-cell attachment (cell adhesion). Additionally, studies indicate that the MLC1 protein may be involved in transporting molecules across the blood-brain barrier and the brain-cerebrospinal fluid barrier, which protect the brain by strictly regulating the substances that enter it.

Health Conditions Related to Genetic Changes

Megalencephalic leukoencephalopathy with subcortical cysts

More than 80 mutations in the MLC1 gene have been found to cause megalencephalic leukoencephalopathy with subcortical cysts type 1, which accounts for 75 percent of all cases of this condition. This disorder affects brain development and function, leading to:

  • Problems with movement
  • Recurrent seizures

Most mutations associated with this condition change single amino acids in the MLC1 protein, altering its structure or preventing the cell from producing the protein entirely. It remains unknown how the lack of MLC1 protein at astroglial cell junctions specifically impairs brain development to cause these symptoms.

Other Names for This Gene

  • KIAA0027
  • LVM
  • megalencephalic leukoencephalopathy with subcortical cysts 1 gene product
  • MLC
  • MLC1_HUMAN
  • VL

Frequently Asked Questions

MLC is inherited in an autosomal‑recessive pattern. Each carrier parent has a 25 % chance of having another affected child, a 50 % chance of having a carrier, and a 25 % chance of having a child without the mutation. Prenatal testing or pre‑implantation genetic diagnosis is available if the family’s specific MLC1 mutations are known.
Yes. Over 80 pathogenic variants in MLC1 have been identified, and confirming a biallelic mutation establishes a definitive diagnosis, guides prognosis, and informs family planning. Testing is usually done by sequencing the entire coding region and copy‑number analysis.
confirmed MLC1 mutation predicts the classic MLC phenotype: macrocephaly, motor delay, and a high likelihood of recurrent seizures. Seizures are often responsive to standard antiepileptic drugs, but breakthrough seizures may require medication adjustments or ketogenic diet under neurologist supervision. Disease progression is usually slow, with many patients maintaining ambulation into adulthood.
Currently, no disease‑modifying therapy exists for MLC. Management focuses on supportive care: physical therapy for motor impairment, seizure control, and monitoring for cyst enlargement with MRI. Some centers enroll patients in clinical trials exploring agents that modulate astroglial function, but these are investigational.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA